On December 21, 2016, SeekingAlpha.com reported that Sinovac’s Chairman and Chief Executive Officer, Weidong Ying paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife, to help advance drug applications and evaluations. Then on May 16, 2017, Sinovac announced that the Securities Exchange Commission is investigating the Company for alleged bribery mentioned in SeekingAlpha‘s article, and that Sinovac would not be able to file its annual financial results on time.
If you are aware of any facts relating to this investigation, or purchased shares of Sinovac, you can assist this investigation by visiting the firm’s site: www.bgandg.com/sva. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC